Dechra Pharmaceuticals (LSE:DPH) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DPH Panoramica delle azioni

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.

Informazioni sull'azienda

DPH analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	1/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 62.48% all'anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Dechra Pharmaceuticals PLC Concorrenti

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£2.2b

Indivior

LSE:INDV

UK£1.2b

GSK

LSE:GSK

UK£65.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Dechra Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	UK£38.66
Massimo di 52 settimane	UK£41.46
Minimo di 52 settimane	UK£24.73
Beta	0.78
1Variazione di 1 mese	0.68%
Variazione a 3 mesi	1.84%
Variazione di 1 anno	32.40%
3Variazione a 3 anni	5.57%
Variazione a 5 anni	60.15%
Variazione dall'IPO	2,828.79%

Notizie e aggiornamenti recenti

Recent updates

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02

Rendimenti per gli azionisti

	DPH	GB Pharmaceuticals	GB Mercato
7D	0.2%	0.1%	-0.3%
1Y	32.4%	20.4%	11.6%

Ritorno vs Industria: DPH ha superato il UK Pharmaceuticals che ha restituito 20.9 % nell'ultimo anno.

Rendimento vs Mercato: DPH ha superato il mercato UK che ha restituito 13.1 % nell'ultimo anno.

Volatilità dei prezzi

Is DPH's price volatile compared to industry and market?
DPH volatility
DPH Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.7%
10% least volatile stocks in GB Market	2.6%

Prezzo delle azioni stabile: DPH non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di DPH è diminuita da 6% a 0% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Dechra Pharmaceuticals con la sua capitalizzazione di mercato?
DPH statistiche fondamentali
Capitalizzazione di mercato	UK£4.40b
Guadagni(TTM)	-UK£27.90m
Ricavi(TTM)	UK£761.50m

5.8x

Rapporto P/S

-157.8x

Rapporto P/E

DPH è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
DPH Conto economico (TTM)
Ricavi	UK£761.50m
Costo del fatturato	UK£331.90m
Profitto lordo	UK£429.60m
Altre spese	UK£457.50m
Guadagni	-UK£27.90m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.24
Margine lordo	56.42%
Margine di profitto netto	-3.66%
Rapporto debito/patrimonio netto	64.6%

Come si è comportato DPH nel lungo periodo?

Vedi performance storica e confronto

DPH Panoramica delle azioni

Premi

Analisi del rischio

Dechra Pharmaceuticals PLC Concorrenti

LSE:HIK

UK£4.4b

AIM:HCM

UK£2.2b

LSE:INDV

UK£1.2b

LSE:GSK

UK£65.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Consensus EPS estimates fall by 10%

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Upcoming dividend of UK£0.13 per share at 1.6% yield

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Full year 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Dechra Pharmaceuticals PLC Announces Executive Changes

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Less than half of directors are independent

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Non-Executive Chairman recently bought UK£99k worth of stock

Consensus EPS estimates increase by 17%

Upcoming dividend of UK£0.12 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

First half 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package